Enterolactone has stronger effects than enterodiol on ovarian cancer

• Main Authors: Huidi Liu (Author), Jianrui Liu (Author), Siwen Wang (Author), Zheng Zeng (Author), Ting Li (Author), Yongfang Liu (Author), Emilio Mastriani (Author), Qing-Hai Li (Author), Hong-Xia Bao (Author), Yu-Jie Zhou (Author), Xiaoyu Wang (Author), Sijing Hu (Author), Shan Gao (Author), Yingying Qi (Author), Zhihang Shen (Author), Hongyue Wang (Author), Miao Yu (Author), Tingting Gao (Author), Randal N. Johnston (Author), Shu-Lin Liu (Author)
• Format: Book
• Published: BMC, 2017-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Ovarian cancer is one of the three leading gynecological malignancies, characterized by insidious growth, highly frequent metastasis, and quick development of drug resistance. As a result, this disease has low 5-year survival rates. Estrogen receptor inhibitors were commonly used...